PEG-MGF
- Category
- Tissue Repair & Recovery
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A PEGylated MGF-related peptide intended to prolong exposure; sustained muscle-repair effects after training have not been established. The case rests entirely on animal and cell studies, and one even found no effect on muscle stem cells. It has never been tested in a human trial, leaving essentially no human safety data and an unresolved, IGF-1-related tumor concern. Not an approved drug in the US; products sold online are unregulated and of uncertain purity.
Read Full recordStudied uses & evidence
Studied uses(7)
Muscle satellite cell activation and skeletal muscle repair
LowAnimal and cell studies suggest satellite cell activation, but one 2014 study found none. No human data.
Cardioprotection and reduced cardiac damage after myocardial infarction
LowConsistent across mouse and sheep heart attack models, reducing cell death, with no human trials yet.
Neuroprotection and promotion of neurogenesis in the aging brain
LowMouse studies show new neuron growth and reduced brain injury in aging models, no human data.
Evidence limits
- Evidence Level
- Preclinical
The cited therapeutic evidence concerns native MGF, synthetic E-domain peptides, gene overexpression or peptide-loaded scaffolds. It is preclinical background and does not establish the effects of PEG-MGF itself. These studies used cell culture and animal models, including mice, rats, rabbits and sheep. Human data are limited to observational studies measuring endogenous MGF/IGF-1Ec mRNA expression in human muscle biopsies after exercise or injury, and in vitro studies using human-derived muscle progenitor cells treated with synthetic MGF peptide (Kandalla et al. 2011). No interventional human trial has administered PEG-MGF or MGF E-domain peptide to human subjects. The preclinical evidence is robust in cardiac protection models but actively contested in skeletal muscle (Fornaro et al. 2014 contradicted satellite cell activation claims). Anti-doping labs have developed detection methods for MGF (Thevis et al. 2014), indicating known illicit use in athletes despite absence of clinical validation.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Active cancer
HighGrowth factor activity may promote tumor cell proliferation.
General cautions
Pregnancy
AbsoluteNo safety data. Growth factor modulation during pregnancy is dangerous.
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
Never administered to humans in a controlled clinical trial
HighFornaro et al. 2014 found no effect of MGF peptide on myoblasts/muscle stem cells (efficacy debated)
ModerateIGF-1-related; could theoretically accelerate tumor proliferation
TheoreticalUnregulated products sold online
HighInjection site pain/numbness/redness (anecdotal)
LowMay lower blood glucose; hypoglycemia risk with diabetes meds
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.